SEC Form 4 · accession 0001209191-16-118543
Intellia Therapeutics, Inc. · NTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Caroline Dorsa
Director
Period of report
May 5, 2016
Accepted (ET)
May 9, 2016 · 5:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001652130
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $18.00 | May 5, 2016 | A | 15,176 | A | — | May 4, 2026 | Common Stock | 15,176 | 15,176 | D |
Explanation of responses
- F1This option was granted on May 5, 2016 with respect to 15,176 shares of Common Stock, with 33% vesting on May 5, 2017 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.